Ronald Davis, MD
Urology · Jackson, MSNPI 1255351367
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,296 of the $6,402 with a category attached, or 82.7%. 35 manufacturers reported payments, led by Astellas Pharma US Inc at 24.1% of the total.
Across 254 payments — averaging $25.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$2K
- Johnson & Johnson$846
- Teleflex LLC$614
- Myriad Genetic Laboratories, Inc.$397
- Pfizer$375
- AbbVie$339
- plus $2K from 29 others
What the payments were for
- Food & beverage$5,29683%
- Education$1,10617%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 50 | $1,543 |
| Johnson & Johnson(2 entities) | 37 | $846 |
| Teleflex LLC | 10 | $614 |
| Myriad Genetic Laboratories, Inc. | 15 | $397 |
| Pfizer | 15 | $375 |
| AbbVie(2 entities) | 23 | $339 |
| Bayer | 17 | $305 |
| Procept Biorobotics Corporation | 7 | $277 |
| Boston Scientific | 10 | $268 |
| Endo Pharmaceuticals Inc. | 14 | $247 |
| Dendreon Pharmaceuticals LLC | 8 | $187 |
| Sumitomo Pharma America, Inc. | 8 | $145 |
| Progenics Pharmaceuticals, Inc. | 6 | $138 |
| Dornier Medtech America, Inc | 1 | $114 |
| Urogen Pharma, Inc. | 4 | $67 |
| Myovant Sciences Inc. | 3 | $58 |
| Cook Medical LLC | 2 | $55 |
| Urovant Sciences Inc | 3 | $50 |
| Coloplast | 3 | $43 |
| Steris Corporation | 1 | $36 |
| Endo USA, Inc. | 2 | $35 |
| Amgen | 2 | $32 |
| Calyxo, Inc. | 1 | $28 |
| Merck | 1 | $24 |
| Blue Earth Diagnostics | 1 | $23 |
| Telix Pharmaceuticals | 1 | $22 |
| Olympus America Inc. | 1 | $22 |
| Tolmar Pharmaceuticals, Inc. | 1 | $17 |
| Innovation Technologies Inc | 1 | $16 |
| Hollister Incorporated | 1 | $16 |
| 180 Medical, Inc. | 1 | $15 |
| Photocure Inc | 1 | $14 |
| Axonics, Inc. | 1 | $13 |
| Tersera Therapeutics LLC | 1 | $12 |
| Ambu Inc. | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UroLift System$280
- XTANDI$250
- UroLift$163
- Prolaris$123
- Dornier MedTech$114
How this compares
$6,402 in reported general payments places this provider in the 75th percentile of 94 urology providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 25 | $341,294 |
| ErleadaApalutamide | 20 | $287,633 |
| MyrbetriqMirabegron | 92 | $45,341 |
| GemtesaVibegron | 57 | $42,095 |
| Tamsulosin Hcl | 517 | $5,843 |
| Methenamine Hippurate | 63 | $4,937 |
| Dutasteride | 150 | $3,795 |
| Bethanechol Chloride | 55 | $2,493 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 51 | $1,097 |
| Amitriptyline Hcl | 114 | $973 |
| Potassium Citrate ErPotassium Citrate | 24 | $850 |
| Oxybutynin Chloride ErOxybutynin Chloride | 33 | $734 |
| Silodosin | 12 | $559 |
| Finasteride | 61 | $495 |
| Bicalutamide | 16 | $454 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $1,543 | $386,635117 claims |
| Johnson & JohnsonErleada | $846 | $287,63320 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $145 | $42,09557 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 94 urology providers in Mississippi.
Other urology in Jackson
- Harold BlalockJackson$15K
- Patrick DailyJackson$12K
- Mark RunnelsJackson$10K
- Allen HarawayJackson$8K
- John AdamsJackson$8K
- Michael WoodJackson$8K
- Chadwick HuckabayJackson$8K
- Felix Gordon JrJackson$6K
- Kieran HynesJackson$6K
- Matthew MossJackson$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.